HER2 antibody for ADC (Trastuzumab biosimilar)

Monoclonal human IgG1 antibody against HER2 for antibody-drug conjugation

InvivoGen provides Anti-HER2-hIgG1, a monoclonal antibody (mAb) specifically developed for the generation of antibody-drug conjugates (ADCs). This mAb features:

• the variable region of trastuzumab, which specifically targets the human epidermal growth factor 2 (HER2),
• a human IgG1 constant region that displays high effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC).

InvivoGen's Anti-HER2-hIgG1 has been generated by recombinant DNA technology, produced in CHO cells, and purified by affinity chromatography.

HER2 background

HER2 (human epidermal growth factor receptor 2), also known as HER2/neu or ERBB2, is a transmembrane protein expressed by epithelial cells that plays an important role in normal cell growth and differentiation [1]. HER2 overexpression causes uncontrollable cell proliferation, as most particularly evidenced in breast and ovarian cancers [1].
Therapeutic strategies aiming at killing HER2+ cancer cells use the FDA-approved trastuzumab, an anti-HER2-hIgG1 antibody. Binding of trastuzumab to HER2 results in cell death through different mechanisms, including antibody-dependent cell-mediated cytotoxicity and phagocytosis [2,3]. Antibody-drug conjugates (ADCs) combining trastuzumab with cytotoxic payloads allow targeted drug delivery to cancer cells in addition to the mAb-mediated effector functions [4].

In a co-culture of HER2+ tumor cells and human peripheral blood monocytes (PBMCs), ADCs combining InvivoGen's Anti-HER2-hIgG1 and STING or TLR7 agonists induce a significantly higher production of IL-6 and CXCL10 pro-inflammatory cytokines than unconjugated agonists or negative control ADCs (see Figures).

Key features of Anti-HER2-hIgG1

• Clinically-relevant variable region targeting human HER2 (trastuzumab)
• Human IgG1 constant region for high effector functions
• Functionally validated by flow cytometry and ADC-based cellular assays
• The absence of bacterial contamination has been confirmed

InvivoGen offers conjugatable PRR ligands for building immunostimulatory Anti-HER2 ADCs.
You may choose from TLR7 and STING agonists:
- Conjugatable TLR7 agonists: TL7-887 and TL7-975
- Conjugatable STING agonists: STG-982 and STG-968

Learn more about bioconjugation

References

1. Rubin I. & Yarden Y. 2001. The basic biology of HER2. Ann Oncol.12 Suppl 1:S3-8.
2. Collins DM. et al., 2012. Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann Oncol. 23(7):1788-95.
3. Petricevic B. et al., 2013. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. J Transl Med. 11:307.
4. Tarantino P. et al., 2022. Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 72:165-182.